StockData
Royalty Pharma plc logo

Royalty Pharma plc

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3053% above fair value
$68.45+0.73 (+1.08%)

Close on Nov 20, 2026Market cap $39.36BP/E 38.9Yield –

Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration by Quarter

Investment-Grade Senior Notes Weighted-Average Duration (years)

Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration: 12.0 years in Q3 2026.

Latest, Q3 2026
12.0
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below

Where the Q3 2026 figure comes from

“$8.8bn with weighted average duration of ~12 years; total leverage of 2.7x(1), net leverage of 2.5x(2)”

Source: Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗

Reported in Royalty Pharma Quarterly Earnings Presentations (Q4 2025 - Q3 2026).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInvestment-Grade Senior Notes Weighted-Average Duration (years)Year on yearSource
Q3 2026Sep 30, 202612.0–Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗
Q2 2026Jun 30, 202612.0–Royalty Pharma Quarterly Earnings Presentation (Q2 2026) ↗
Q1 2026Mar 31, 202612.0–Royalty Pharma Quarterly Earnings Presentation (Q1 2026) ↗
Q4 2025Dec 31, 202513.0–Royalty Pharma Quarterly Earnings Presentation (Q4 2025) ↗

Cite this data

StockData. (2026). Royalty Pharma Investment-Grade Senior Notes Weighted-Average Duration (years), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Royalty Pharma SEC filings and investor materials. https://stockdatahq.com/stocks/rprx/kpis/debt-weighted-average-duration

See every metric in the Royalty Pharma KPI table. Data updated Nov 14, 2026.

See a number that looks wrong?